Clinical Trials
8 trialsNCT03635983 2025-04-01
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT04209114 2024-06-27
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
NCT03548467 2023-04-21
DIRECT-01
Nykode Therapeutics ASA
Phase 1/2 Completed
NCT03785925 2023-03-28
PIVOT-10
Nektar Therapeutics
Phase 2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03745807 2021-10-04
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT02869295 2021-07-29
NKTR-214
Nektar Therapeutics
Phase 1/2 Completed